Companies › Xcovery Holdings
1 active drug program in 1 registered trial: 1 Phase 3; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ensartinib (X-396) ALK tyrosine kinase receptor inhibitor | ALK | Phase 3 | Non-small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02767804 | Ensartinib (X-396) | Phase 3 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
Shenzhen TargetRx Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.